全文获取类型
| 收费全文 | 6941篇 |
| 免费 | 771篇 |
| 国内免费 | 21篇 |
专业分类
| 耳鼻咽喉 | 90篇 |
| 儿科学 | 233篇 |
| 妇产科学 | 130篇 |
| 基础医学 | 805篇 |
| 口腔科学 | 63篇 |
| 临床医学 | 1155篇 |
| 内科学 | 1566篇 |
| 皮肤病学 | 90篇 |
| 神经病学 | 560篇 |
| 特种医学 | 144篇 |
| 外科学 | 765篇 |
| 综合类 | 45篇 |
| 一般理论 | 2篇 |
| 预防医学 | 849篇 |
| 眼科学 | 71篇 |
| 药学 | 418篇 |
| 中国医学 | 2篇 |
| 肿瘤学 | 745篇 |
出版年
| 2024年 | 18篇 |
| 2023年 | 171篇 |
| 2022年 | 130篇 |
| 2021年 | 300篇 |
| 2020年 | 195篇 |
| 2019年 | 201篇 |
| 2018年 | 262篇 |
| 2017年 | 238篇 |
| 2016年 | 222篇 |
| 2015年 | 244篇 |
| 2014年 | 318篇 |
| 2013年 | 416篇 |
| 2012年 | 517篇 |
| 2011年 | 503篇 |
| 2010年 | 296篇 |
| 2009年 | 334篇 |
| 2008年 | 384篇 |
| 2007年 | 433篇 |
| 2006年 | 425篇 |
| 2005年 | 427篇 |
| 2004年 | 354篇 |
| 2003年 | 349篇 |
| 2002年 | 299篇 |
| 2001年 | 60篇 |
| 2000年 | 36篇 |
| 1999年 | 60篇 |
| 1998年 | 62篇 |
| 1997年 | 48篇 |
| 1996年 | 55篇 |
| 1995年 | 49篇 |
| 1994年 | 38篇 |
| 1993年 | 41篇 |
| 1992年 | 20篇 |
| 1991年 | 14篇 |
| 1990年 | 14篇 |
| 1989年 | 15篇 |
| 1988年 | 14篇 |
| 1987年 | 10篇 |
| 1986年 | 7篇 |
| 1985年 | 9篇 |
| 1984年 | 32篇 |
| 1983年 | 18篇 |
| 1982年 | 15篇 |
| 1981年 | 16篇 |
| 1980年 | 8篇 |
| 1979年 | 11篇 |
| 1978年 | 5篇 |
| 1977年 | 7篇 |
| 1976年 | 6篇 |
| 1974年 | 5篇 |
排序方式： 共有7733条查询结果，搜索用时 15 毫秒
91.
92.
93.
94.
Alison E. Brown Ellen Heinsbroek Meaghan M. Kall Hester Allen Kazim Beebeejaun Paula Blomquist Ines Campos-Matos Colin N.J. Campbell Hamish Mohammed Katy Sinka Theresa Lamagni Nicholas Phin the PHE COVID- Mortality Working Group Gavin Dabrera 《Emerging infectious diseases》2021,27(5):1468
Of the 58,186 coronavirus deaths among adults in England during March–December 2020, 77% occurred in hospitals, 93% were in patients >60 years, and 91% occurred within 28 days of positive specimen. Cumulative mortality rates were highest among persons of Black, Asian, other, or mixed ethnicities and in socioeconomically deprived areas. 相似文献
95.
Blythe Adamson Wafaa El-Sadr Dobromir Dimitrov Theresa Gamble Geetha Beauchamp Josh J. Carlson Louis Garrison Deborah Donnell 《Value in health》2019,22(2):194-202
Objective
To evaluate the cost-effectiveness of financial incentives for human immunodeficiency virus (HIV) viral suppression compared to standard of care.Study Design
Mathematical model of 2-year intervention offering financial incentives ($70 quarterly) for viral suppression (<400 copies/ml3) based on the HPTN 065 clinical trial with HIV patients in the Bronx, NY and Washington, D.C.Methods
A disease progression model with HIV transmission risk equations was developed following guidelines from the Second Panel on Cost-Effectiveness in Health and Medicine. We used health care sector and societal perspectives, 3% discount rate, and lifetime horizon. Data sources included trial data (baseline N = 16,208 patients), CDC HIV Surveillance data, and published literature. Outcomes were costs (2017 USD), quality-adjusted life years (QALYs), HIV infections prevented, and incremental cost-effectiveness ratio (ICER).Results
Financial incentives for viral suppression were estimated to be cost-saving from a societal perspective and cost-effective ($49,877/QALY) from a health care sector perspective. Compared to the standard of care, financial incentives gain 0.06 QALYs and lower discounted lifetime costs by $4210 per patient. The model estimates that incentivized patients transmit 9% fewer infections than the standard-of-care patients. In the sensitivity analysis, ICER 95% credible intervals ranged from cost-saving to $501,610/QALY with 72% of simulations being cost-effective using a $150,000/QALY threshold. Modeling results are limited by uncertainty in efficacy from the clinical trial.Conclusions
Financial incentives, as used in HTPN 065, are estimated to improve quality and length of life, reduce HIV transmissions, and save money from a societal perspective. Financial incentives offer a promising option for enhancing the benefits of medication in the United States. 相似文献96.
Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy 
下载免费PDF全文
下载免费PDF全文 Christine L. H. Snozek Theresa N. Kinard Jill Adamski 《Journal of clinical apheresis》2018,33(3):439-443
This report describes a patient with light chain myeloma and acute renal injury. Serum kappa free light chain (FLC) was extremely elevated, >33,000 mg/dL. Treatment with therapeutic plasma exchange (TPE) started day 2 for biopsy‐confirmed cast nephropathy. Bortezomib‐containing chemotherapy was initiated on day 5, and hemodialysis for tumor lysis syndrome on day 7. TPE alone decreased kappa FLC >70% by day 5, indicating direct FLC removal was successful in this patient. A total of 25 TPE procedures were performed in a 31‐day hospitalization. Hemodialysis was discontinued after 3 months, and the patient's renal function and kappa FLC remain stable. Although the use of TPE for FLC removal is controversial, recent evidence supports its use as adjuvant therapy for acute renal injury secondary to myeloma cast nephropathy. TPE can be effective for rapidly reducing FLC; however, several TPE procedures might be required to reduce the risk of hemodialysis dependency. 相似文献
97.
98.
Theresa Clifford 《Journal of PeriAnesthesia Nursing》2018,33(6):1006-1007
99.
100.
Factors that affect implementation of a nurse staffing directive: results from a qualitative multi‐case evaluation 下载免费PDF全文
下载免费PDF全文